Loading
HORRAD found no overall survival benefit from irradiating the prostate in men presenting with bone metastases, though a possible gain in those with few metastases fed into STAMPEDE's later positive finding.
HORRAD randomised 432 men with newly diagnosed prostate cancer and bone metastases to androgen deprivation therapy with or without external beam radiotherapy to the prostate. Median overall survival was 45 months with radiotherapy and 43 months without (hazard ratio 0.90, not significant); time to PSA progression improved and a subgroup with fewer than five metastases suggested benefit (Boeve and colleagues, European Urology 2019). STAMPEDE arm H later confirmed a survival gain from prostate radiotherapy in low-volume metastatic disease.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
432 enrolled.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.